

**29 September 2011**

**Physiomics plc  
("Physiomics" or the "Company")**

**Joint services alliance executed with Jubilant Biosys**

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has now executed its Joint Services Alliance with Jubilant Biosys Limited ("Jubilant").

Further to the announcement of 31 August 2010 and 8 March 2011, Physiomics can confirm that the Alliance Agreement between the Company and Jubilant (the "Agreement") has now been executed.

Pursuant to the terms of the Agreement (which is not exclusive) both parties have agreed to work together for the purpose of maximising their respective income from joint business opportunities. The Directors believe that the combination of Jubilant's experimental capabilities and Physiomics' Virtual Tumour technology will provide an unique proposition to potential customers. Moreover, it potentially offers clients a 'one-stop shop' to select optimal drug regimens as they design their early clinical studies.

Whilst no immediate revenue is generated by Physiomics on signing this agreement, the Directors believe that through Jubilant's global business network they will have an increased number of opportunities to market the Virtual Tumour technology from which new sales may be generated.

Dr Mark Chadwick, CEO of Physiomics, said

"We are delighted to be teaming up with Jubilant, a global leader in drug discovery and development services. We anticipate that joining forces with them will lead to enhanced project flow and further development of our services."

Enquiries:

**Physiomics plc**

Dr Mark Chadwick, CEO

+44 (0)1865 784 980

**WH Ireland Limited**

Katy Mitchell

+44 (0) 161 832 2174

**Information on Physiomics plc**

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behavior to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as \$242 million, from the current estimate of around \$800 million<sup>1</sup>.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit [www.physiomics-plc.com](http://www.physiomics-plc.com)

SystemCell® is a registered trademark of Physiomics plc

<sup>1</sup>Tufts Centre Impact Report 2002